Results 141 to 150 of about 1,178,962 (294)

Steroid-sparing strategies for managing immune-related adverse events. [PDF]

J Immunother Cancer
Huang JJ, YousefiAsl M, Singh N, Grivas P, Bhatia S.   +4 more
europepmc   +1 more source

Absence of an Association Between Plasmodium falciparum Infection and Post-Ivermectin Loa-Related Non-Neurologic Serious Adverse Events [PDF]

, 2014
Joël Fokom Domgue, Sébastien D. S. Pion, Racéline Kamkumo Gounoue, Julie Akame, Patrick Nguipdop‐Djomo, Nana Twum-Danso, B Thylefors, Michel Boussinesq, Joseph Kamgno   +8 more
openalex   +1 more source

Trends in Dermatopolymyositis Mortality, 1999–2022: A Nationwide Population‐Based Study, United States

Arthritis Care &Research, EarlyView.
We report the national burden of dermatopolymyositis mortality over the past quarter century using the US national vital statistics data. Age‐standardized mortality rates for dermatopolymyositis decreased at an annual rate of 3.8% each year, which was higher than the annual percent decrease for deaths from all other causes.
Elizabeth Matz, Ram R. Singh
wiley   +1 more source

Acute Response in the Noninfarcted Myocardium Predicts Long-Term Major Adverse Cardiac Events After STEMI

, 2022
Mayooran Shanmuganathan, Ambra Masi, Matthew K. Burrage, Rafail A. Kotronias, Alessandra Borlotti, Roberto Scarsini, Abhirup Banerjee, Dimitrios Terentes‐Printzios, Qiang Zhang, Evan Hann, Elizabeth M. Tunnicliffe, Andrew Lucking, Jeremy P. Langrish, Rajesh Kharbanda, Giovanni Luigi De Maria, Adrian Banning, Robin P. Choudhury, Keith M. Channon, Stefan K. Piechnik, Vanessa M. Ferreira   +19 more
openalex   +1 more source

Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, EarlyView.
Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

Relationship Between the Nurse–Patient Ratio and Adverse Events in Conventional Hospitalization Units in a Third‐Level Hospital [PDF]

Juan David Fernández-Sánchez, Fernando Andrés‐Pretel, Verónica Ortiz-Diaz, Milagros Molina‐Alarcón, Cristina Lozano-Hernández   +4 more
openalex   +1 more source

Serum Uric Acid Levels in Older Adults: Associations With Clinical Outcomes and Implications for Reference Intervals in Those Aged 70 Years and Over

Arthritis Care &Research, EarlyView.
Objective Reports have linked both high and low serum uric acid (SUA) levels to adverse health outcomes. This study aimed to establish a reference interval for SUA in older adults and assessed its association with clinically relevant outcomes in relatively healthy, community‐dwelling individuals aged ≥70 years old.
Amanda J. Rickard, Cammie Tran, Hans G. Schneider, Flavia M. Cicuttini, Anita E. Wluka, Ego Seeman, Johannes T. Neumann, Md Nazmul Karim, Zhen Zhou, Sultana Monira Hussain, David P. Q. Clark, Daniel Clayton‐Chubb, Andrew M. Tonkin, Lawrence J. Beilin, Robyn L. Woods, John J. McNeil   +15 more
wiley   +1 more source

Age and Sex Differences in Adverse Events Associated With Antipsychotics: An Analysis of the FDA Adverse Events Database. [PDF]

Int J Geriatr Psychiatry
Ramin T, Peter JU, Schneider M, Dahling V, Zolk O.   +4 more
europepmc   +1 more source

Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative

, 2016
Bryce B. Reeve, Molly McFatrich, Laura C. Pinheiro, Meaghann S. Weaver, Lillian Sung, Janice S. Withycombe, Justin N. Baker, Jennifer W. Mack, Mia K. Waldron, Deborah Gibson, Deborah Tomlinson, David R. Freyer, Catriona Mowbray, Shana Jacobs, Diana Palma, Christa E. Martens, Stuart Gold, Kathryn D. Jackson, Pamela S. Hinds   +18 more
openalex   +1 more source

Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko, Ross Wilson, Nicola Dalbeth, J. Haxby Abbott, Lisa Stamp   +4 more
wiley   +1 more source